Canesten Cream
Out of date information, search anotherSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Canesten Cream Combi Internal & External Creams
Canesten Thrush Combi Internal & External Creams 10% w/w / 2% w/w vaginal cream & cream
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Canesten Thrush Internal Cream contains Clotrimazole 10% w/w.
Canesten Thrush External Cream contains Clotrimazole 2% w/w.
Excipient with known effect: cetostearyl alcohol For the full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Vaginal cream White vaginal cream
Cream White cream
4. CLINICAL PARTICULARS
4.1. Therapeutic Indications
The internal cream is recommended for the treatment of candidal vaginitis.
The external cream is recommended for the treatment of candidal vulvitis. It should be used as an adjunct to treatment of candidal vaginitis.
These products should only be used if candidal vulvovaginitis (thrush) was previously diagnosed by a doctor.
4.2 Posology and method of administration
Adults
The internal cream should be administered intravaginally using the applicator supplied. The contents of the filled applicator (5g) should be inserted as deeply as possible into the vagina, preferably at night.
The external cream should be thinly applied to the vulva and surrounding area, two or three times daily and rubbed in gently.
Treatment with the external cream should be continued until symptoms of the infection disappear. However, if after concomitant treatment of the vaginitis, the symptoms do not improve within seven days, the patient should consult a physician.
Generally:
Treatment during the menstrual period should be avoided due to the risk of the cream being washed out by the menstrual flow. The treatment should be finished before the onset of menstruation.
Do not use tampons, intravaginal douches, spermicides or other vaginal products while using this product.
Vaginal intercourse should be avoided in case of vaginal infection and while using this product because the partner could become infected.
Children
Not for use in children under 16.
4.3 Contraindications
Hypersensitivity to clotrimazole or any of the other excipients listed in section 6.1.
Do not use to treat nail or scalp infections.
4.4 Special warnings and precautions for use
These products contain cetostearyl alcohol, which may cause local skin reactions (e.g. contact dermatitis).
Before using Canesten Thrush Combi Internal & External Creams medical advice must be sought if any of the following are applicable: -
- more than two infections of candidal vaginitis in the last 6 months
- previous history of a sexually transmitted disease or exposure to partner with sexually transmitted disease
- pregnancy or suspected pregnancy
- aged under 16 or over 60 years
- known hypersensitivity to imidazoles or other vaginal antifungal products
The creams should not be used if the patient has any of the following symptoms whereupon medical advice should be sought: -
- irregular vaginal bleeding
- abnormal vaginal bleeding or a blood-stained discharge
- vulval or vaginal ulcers, blisters or sores
- lower abdominal pain or dysuria
- any adverse events such as redness, irritation or swelling associated with the treatment
- fever or chills
- nausea or vomiting
- diarrhoea
- foul smelling vaginal discharge
If no improvement in symptoms is seen after 7 days the patient should consult their doctor.
4.5 Interaction with other medicinal products and other forms of interaction
Laboratory tests have suggested that, when used together, this product may cause damage to latex contraceptives. Consequently the effectiveness of such contraceptives may be reduced. Patients should be advised to use alternative precautions for at least five days after using this product.
Concomitant medication with vaginal clotrimazole and oral tacrolimus (FK-506; immunosuppressant) might lead to increased tacrolimus plasma levels and similarly with sirolimus. Patients should thus be closely monitored for signs and symptoms of tacrolimus or sirolimus overdosage, if necessary by determination of the respective plasma levels.
4.6 Fertility, pregnancy and lactation
Fertility:
No human studies of the effects of clotrimazole on fertility have been performed, however, animal studies have not demonstrated any effects of the drug on fertility.
Pregnancy:
There are limited amount of data from the use of clotrimazole in pregnant women. Animal studies with clotrimazole have shown reproductive toxicity at high oral doses (see section 5.3). At the low systemic exposures of clotrimazole following vaginal treatment, harmful effects with respect to reproductive toxicity are not predicted.
Clotrimazole can be used during pregnancy, but only under the supervision of a physician or midwife.
During pregnancy the treatment should be carried out with clotrimazole pessary, since these can be inserted without using an applicator.
Lactation:
Available pharmacodynamic/toxicological data in animals have shown excretion of clotrimazole/metabolites in milk after intravenous administration (see section 5.3). A risk to the suckling child cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from clotrimazole therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
4.7 Effects on ability to drive and use machines
The medication has no or negligible influence on the ability to drive or use machinery.
4.8 Undesirable effects
As the listed undesirable effects are based on spontaneous reports, assigning accurate frequency of occurrence for each is not possible.
Immune system disorders:
allergic reaction (syncope, hypotension, dyspnea, urticaria, pruritus)
Canesten Internal Cream Reproductive system and breast disorders:
genital peeling, pruritus, rash, oedema, erythema, discomfort, burning, irritation, pelvic pain, vaginal haemorrhage.
Gastrointestinal disorders: abdominal pain
Canesten Cream
Skin and subcutaneous tissue disorders: blisters, discomfort/pain, oedema, erythema, irritation, peeling/exfoliation, pruritus, rash, stinging/burning
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
4.9 Overdose
No risk of acute intoxication is seen as it is unlikely to occur following a single vaginal or dermal application of an overdose (application over a large area under
conditions favourable to absorption) or inadvertent oral ingestion. There is no specific antidote.
However, in the event of accidental oral ingestion, routine measures such as gastric lavage should be performed only if clinical symptoms of overdose become apparent (e.g. dizziness, nausea or vomiting). Gastric lavage should be carried out only if the airway can be protected adequately.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Gynaecological antiinfectives and antiseptics -
imidazole derivatives
ATC Code: G01A F02
Mechanism of Action
Clotrimazole acts against fungi by inhibiting ergosterol synthesis. Inhibition of ergosterol synthesis leads to structural and functional impairment of the fungal cytoplasmic membrane.
Clotrimazole has a broad antimycotic spectrum of action in vitro and in vivo, which includes dermatophytes, yeasts, moulds, etc.
Under appropriate test conditions, the MIC values for these types of fungi are in the region of less than 0.062-8.0 pg/ml substrate. The mode of action of clotrimazole is fungistatic or fungicidal depending on the concentration of clotrimazole at the site of infection. In-vitro activity is limited to proliferating fungal elements; fungal spores are only slightly sensitive.
Primarily resistant variants of sensitive fungal species are very rare; the development of secondary resistance by sensitive fungi has so far only been observed in very isolated cases under therapeutic conditions.
5.2. Pharmacokinetic Properties
Pharmacokinetic investigations after vaginal application have shown that only a small amount of clotrimazole (3 - 10% of the dose) is absorbed. Due to the rapid hepatic metabolism of absorbed clotrimazole into pharmacologically inactive metabolites the resulting peak plasma concentrations of clotrimazole after vaginal application of a 500mg dose were less than 10 ng/ml, reflecting that clotrimazole applied intravaginally does not lead to measurable systemic effects or side effects.
5.3. Preclinical Safety Data
Non-clinical data reveal no special hazard for humans based on studies of repeated dose toxicity, genotoxicity and carcinogenicity.
Clotrimazole was not teratogenic in reproductive toxicity studies in mice, rats and rabbits. In rats high oral doses were associated with maternal toxicity, embryotoxicity, reduced fetal weights and decreased pup survival.
In rats clotrimazole and/or its metabolites were secreted into milk at levels higher than in plasma by a factor of 10 to 20 at 4 hrs after administration, followed by a decline to a factor of 0.4 by 24 hrs.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Canesten Thrush Internal Cream contains:
Sorbitan stearate Poly sorb ate 60 Cetyl palmitate Cetostearyl alcohol Isopropyl myristate Benzyl alcohol Purified water
Canesten Thrush External Cream contains:
Sorbitan stearate Poly sorb ate 60 Cetyl palmitate Cetostearyl alcohol Octyldodecanol Benzyl alcohol Purified Water
6.2. Incompatibilities
Not applicable
6.3. Shelf life
24 months.
6.4. Special precautions for storage
Do not store above 25°C.
6.5 Nature and contents of container
Canesten Thrush Internal Cream:
A single dose applicator consisting of a body of HDPE (lupolene or hostalene), piston of LDPE, cap of LDPE, with a separate plunger of polystyrene. One applicator is contained in a blister pack. Pack size 5g.
Canesten Thrush External Cream:
The cream is filled into Aluminium tubes (10g) with internal lacquer coating, latex stopper and HDPE screw top.
The blister pack and tube are enclosed in a cardboard carton.
6.6 Special precautions for disposal
No special requirements.
7. MARKETING AUTHORISATION HOLDER
Bayer plc Bayer House Strawberry Hill Newbury, Berkshire RG14 1JA.
United Kingdom
Trading as Bayer plc, Consumer Care Division
8. MARKETING AUTHORISATION NUMBER
PL 00010/0301
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 03/08/2009
10
DATE OF REVISION OF THE TEXT
17/11/2014